<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62818">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288117</url>
  </required_header>
  <id_info>
    <org_study_id>1202 HP</org_study_id>
    <nct_id>NCT02288117</nct_id>
  </id_info>
  <brief_title>Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem</brief_title>
  <official_title>Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Waldemar Link GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Waldemar Link GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this PMCF is to collect clinical and radiographic outcome information on
      Total Hip Arthroplasty (THA) performed with LINK® SP-CL® Hip Prosthesis Stem under routine
      conditions.

      The results collected will be used to clinically confirm the performance and safety of the
      LINK® SP-CL® Hip Prosthesis Stem in terms of the manufacturer's obligation to perform a
      PMCF. Furthermore the results can be used for future regulatory processes if needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post Market Clinical Follow-ups (PMCF) through observational studies are an important tool
      to detect infrequent complications or problems, events specific to defined patient
      populations and long term performance issues under routine conditions [2,3]. Against this
      background a prospective multi-center outcome study of the LINK® SP-CL® is planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stem Survival Rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication Rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation Rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score (HHS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Hip Score (OHS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forgotten Joint Score (FJS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid Thigh Pain</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Femur Head Necrosis</condition>
  <condition>Femoral Neck Fractures</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mobility-limiting disease, fracture or defect of the hip joint requiring
        primary THA with SP-CL® (i.e. primary or secondary coxarthrosis, osteoarthritis, femoral
        neck fracture, necrosis of the femoral head)

        ·
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Skeletally mature

          -  Subject agrees to comply with the required postoperative management and follow-up
             evaluations

          -  Undergone at least six (6) month of unsuccessful, conservative, non-surgical
             treatment

          -  Patient understands the conditions of the study and is willing and able to comply
             with the postoperative scheduled clinical and radiographic evaluations and the
             prescribed postoperative management.

          -  Patient signed Informed Consent.

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 40 kg/m2

          -  Poor general state of health

          -  Acute and chronic infections, local and systemic

          -  Pharmaceutical or other drug abuse, alcoholism

          -  Allergies to implant materials

          -  Distinctive muscular, nerve, vascular or other diseases which put the affected limb
             at risk

          -  Insufficient / inadequate bone mass- or quality which prevents a stable anchorage of
             the prosthesis

          -  Severe osteoporosis

          -  Foreseeable overload/ overstressing of the joint prosthesis

          -  Acetabular defects

          -  Female patient who is pregnant or plans to became pregnant during the course of the
             study

          -  Prisoner

          -  Patient who, as judged by the surgeon, is mentally incompetent or is unlikely to be
             compliant with the prescribed postoperative routine and follow-up evaluation schedule

          -  Patient who has not signed the Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Gehrke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HELIOS Endo-Klinik Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulla Waegner, M. Sc.</last_name>
    <phone>+49 (0)40 53575-</phone>
    <phone_ext>0</phone_ext>
    <email>studies@linkhh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Füchtmeier, Prof. Dr.</last_name>
      <phone>+49 (0)941 369-</phone>
      <phone_ext>0</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS ENDO-Klinik</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Gehrke, Prof. Dr.</last_name>
      <phone>+49 40 3197-</phone>
      <phone_ext>0</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Peter Stangenberg, Dr. med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>L'Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milan</city>
        <zip>1-20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Mineo, Prof.</last_name>
    </contact>
    <contact_backup>
      <last_name>Massimo Franceschini, Dott.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Rafael</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Pons Cabrafiga, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.linkorthopaedics.com/sp-cl/en/</url>
    <description>Manufacturer website, hip stem SP-CL</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 14, 2016</lastchanged_date>
  <firstreceived_date>November 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMCF</keyword>
  <keyword>Post Market Clinical Follow up</keyword>
  <keyword>SP-CL</keyword>
  <keyword>anatomic stem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Femoral Neck Fractures</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
